Login to Your Account

ImClone Suffers Erbitux Setback, Says It Won t Need New Trials

By Kim Coghill

Thursday, January 3, 2002
Analysts say the FDA s failure to accept ImClone Systems Inc. s rolling biologics license application for Erbitux in irinotecan-refractory colorectal cancer is expected to delay market launch by about six months.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription